Monster Energy is changing how consumers consume their products with a new addition that cuts out sugar.
“Consumers have been asking for years when we would release a sugar-free version of the OG Monster,” said Dan McHugh, Monster Energy CMO. “But we didn’t want to do it until we had the formula just right — and we believe we have nailed it.”
Zero Energy, the brand’s latest launch, contains 160 mg of caffeine and zero sugar and looks to help improve mental performance and focus the company said.
“We are very proud of our existing sugar-free Monster Energy Ultra line, and all of its incredible innovative flavors,” said McHugh. “But we were long-overdue a zero-sugar version of our flagship flavor. The time of Monster Energy Zero Sugar is now.”
Monster Energy Zero Sugar is now available online and in retail locations carrying the brand’s products.
GNC provides holistic health solutions with 50 Plus line
GNC is expanding upon its holistic health solutions by unveiling a new way consumers who are aged 50 years old and older can obtain their essential daily nutrients.
New from the Pittsburgh-based company is the Mega Men and Women’s 50+ Multivitamin Gummies.
‘GNC Mega Men and GNC Women’s products are great solutions for consumers that need daily support to Live Well,” said Kevin Maloberti, vice president of merchandising at GNC. “These gummies provide clinically studied blends that are shown to work throughout your wellness journey. Our new GNC Mega Men and GNC Women’s 50+ Multivitamin Gummies are a celebration of our commitment to consumer-centric innovation which we hope to see amplify the well-being and everyday health of our consumers.”
Both new launches provide consumers with vitamins and minerals to aid in supporting overall enhanced quality of life and longevity, the company said.
GNC Mega Men and Women’s 50+ Multivitamin Gummies are available for purchase at GNC stores and online.
Native’s Candy Shop collection sweetens the personal care aisle
Ahold Delhaize announced the beginning of its 1 billion Euro share buyback program, which is expected to be completed before the end of 2023.
The purpose of the program is to help reduce the capital of the company by canceling all or part of the common shared acquired through the program, the organization shared.
Executed within the limits of relevant laws and regulations, the existing authority granted Ahold Delhaize’s 2022 annual general meeting of shareholders on April 12, 2022, and the authority if granted by the annual general meeting on April 12, 2023.
The share buyback program is executed in one or several tranches. For each of them, an intermediary is mandated to execute the purchase of the shares at his own discretion during open and closed periods in compliance with the Market Abuse Regulation and within pre-defined execution parameters.
Shares are bought in the market and accumulated on the treasury share account until cancellation. Pursuant to the relevant statutory provisions, cancellation may not be effected earlier than two months after a resolution to cancel shares is adopted and publicly announced. Ahold Delhaize is committed to the share buyback program, but the program is subject to changes in corporate activities, such as but not limited to material M&A activity.
Olay combines niacinamide, peptides to strengthen skin
The brand launched its new Regenerist Niacinamide + Peptide 24 Face Moisturizer, which looks to strengthen skin, even complexions and visibly correct wrinkles.
Featuring a formula that provides 24-hour hydration that looks to hydrate and repair the skin for a stronger barrier, it contains 99% pure niacinamide, peptides and glycerin to penetrate 10 layers deep in the skin’s surface, the company said.
Olay’s Regenerist Niacinamide + Peptide 24 Face Moisturizer retails for $30.
Roche receives FDA nod for Lunsumio
The Food and Drug Administration has approved Roche’s Lunsumio (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Lunsumio, a CD20xCD3 T-cell engaging bispecific antibody, represents a new class of fixed-duration cancer immunotherapy, which is off-the-shelf and readily available, so that patients do not have to wait to start treatment. Lunsumio will be available in the United States in the coming weeks, the company said.
“This approval is a significant milestone for people with relapsed or refractory follicular lymphoma, who have had limited treatment options until now,” said Elizabeth Budde, Haematologic Oncologist and associate professor at the City of Hope division of Lymphoma, department of Hematology and Hematopoietic Cell Transplantation, and Lunsumio clinical trial investigator. “As a first-in-class T-cell engaging bispecific antibody that can be initiated in an outpatient setting, Lunsumio’s high response rates and fixed-duration could change the way advanced follicular lymphoma is treated.”
“Despite treatment advances, follicular lymphoma remains incurable and relapse is common, with outcomes worsening following each consecutive treatment,” said Levi Garraway, Roche’s chief medical officer and head of global product development. “Lunsumio represents our first approved T-cell engaging bispecific antibody and builds on our legacy of more than 20 years of innovation in blood cancer.”